Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Somatic Mutations and Co-Mutations Predict AML Risk in Women

According to results from a deep-sequencing analysis published in Nature Medicine, women with mutations of the TP53 and IDH genes in the absence of...

FDA Places Partial Clinical Hold on AML and MDS Trial

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on a phase I/II trial of OXi4503, a vascular disrupting agent...
On location

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...
On location

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...
On location

Higher-Dose Daunorubicin No More Effective Than Lower Doses in AML

Escalating daunorubicin doses from 60 mg/m2 to 90 mg/m2 in a 7+3 induction regimen consisting of daunorubicin and cytarabine did not increase response rates...

FDA Approves IDH Inhibitor for Patients with AML

The U.S. Food and Drug Administration (FDA) has approved ivosidenib as the first IDH1 inhibitor for patients with relapsed or refractory acute myeloid leukemia...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...

Treating MRD With Azacitidine in Patients With High-Risk AML and MDS

For 58 percent of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at high risk for relapse, treatment of minimal residual disease...
WIB_icon

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...
WIB_icon

Single-Agent Vadastuximab Talirine Active, Tolerable in AML

In a first-in-human study of patients with CD33-positive acute myeloid leukemia (AML), treatment with single-agent vadastuximab talirine (a CD33-targeted antibody-drug conjugate) resulted in a...
Advertisement

Current Issue

December 2021 Volume 7 Issue 15

This issue explores doctor deserts, celebrates the 50th anniversary of the National Cancer Act, and more.

Block title